Literature DB >> 16415902

The basic secretagogue compound 48/80 activates G proteins indirectly via stimulation of phospholipase D-lysophosphatidic acid receptor axis and 5-HT1A receptors in rat brain sections.

Ville A B Palomäki1, Jarmo T Laitinen.   

Abstract

The basic secretagogues, such as compound 48/80 (c48/80) and mastoparans, are widely used histamine-releasing agents and their mechanism of action is commonly attributed to a direct, receptor-bypassing property to activate the G(i/o) class of G proteins. We tested here whether c48/80 could directly stimulate [(35)S]guanosine-5'-[gamma-thio]triphosphate ([(35)S]GTPgammaS) binding to rat brain sections in an attempt to visualize the entire signaling pool of G(i/o) in its native neuroanatomical context. Instead of direct G(i/o) activation, c48/80 (100 microg ml(-1)) from various suppliers stimulated brain phospholipase D (PLD) activity, leading to the generation of endogenous phospholipids capable of activating brain white matter-enriched, G(i/o)-coupled lysophosphatidic acid (LPA) receptors. This response was sensitive to 1-butanol and was potently reversed by the LPA(1)/LPA(3) receptor-selective antagonist Ki16425 (IC(50) 59+/-13 nM, mean+/-s.e.m.), and showed age-dependent decline, closely reflecting known developmental regulation of the PLD-LPA(1) receptor axis in the CNS. In addition, c48/80 was found to modestly activate hippocampal 5-HT(1A) receptors in a pH-dependent and antagonist-sensitive manner. Consistent with the lack of direct G(i/o)-activating properties in brain sections, c48/80 showed no activity in classical membrane [(35)S]GTPgammaS binding assays. Instead, c48/80 from one particular manufacturer elicited non-specific effect in these assays, therefore challenging the previous interpretations regarding the compound's ability to activate G proteins directly. We conclude that c48/80 is not a receptor-bypassing general G protein activator but rather activates PLD, leading to generation of endogenous LPA receptor-activating phospholipids. This property may also contribute to the compound's ability to release histamine from mast cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16415902      PMCID: PMC1751339          DOI: 10.1038/sj.bjp.0706671

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

Review 1.  G protein-dependent activation of mast cell by peptides and basic secretagogues.

Authors:  Xavier Ferry; Stephan Brehin; Rehab Kamel; Yves Landry
Journal:  Peptides       Date:  2002-08       Impact factor: 3.750

Review 2.  Lysophospholipid G protein-coupled receptors.

Authors:  Brigitte Anliker; Jerold Chun
Journal:  J Biol Chem       Date:  2004-03-15       Impact factor: 5.157

3.  The influence of bound GDP on the kinetics of guanine nucleotide binding to G proteins.

Authors:  K M Ferguson; T Higashijima; M D Smigel; A G Gilman
Journal:  J Biol Chem       Date:  1986-06-05       Impact factor: 5.157

4.  Modulation by cationic amphiphilic drugs of serine base-exchange, phosholipase d and intracellular calcium homeostasis in glioma C6 cells.

Authors:  Marta Bobeszko; Rafał Czajkowski; Magdalena Wójcik; Paweł Sabała; Lingsheng Lei; Irena Nalepa; Jolanta Barańska
Journal:  Pol J Pharmacol       Date:  2002 Sep-Oct

Review 5.  Mechanisms of lysophosphatidic acid production.

Authors:  Junken Aoki
Journal:  Semin Cell Dev Biol       Date:  2004-10       Impact factor: 7.727

6.  Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.

Authors:  Hideo Ohta; Koichi Sato; Naoya Murata; Alatangaole Damirin; Enkhzol Malchinkhuu; Junko Kon; Takao Kimura; Masayuki Tobo; Yuji Yamazaki; Tomoko Watanabe; Mikio Yagi; Motoko Sato; Rika Suzuki; Hideko Murooka; Teruyuki Sakai; Tsuyoshi Nishitoba; Dong-Soon Im; Hiromi Nochi; Koichi Tamoto; Hideaki Tomura; Fumikazu Okajima
Journal:  Mol Pharmacol       Date:  2003-10       Impact factor: 4.436

7.  Phospholipase D2 localizes to the plasma membrane and regulates angiotensin II receptor endocytosis.

Authors:  Guangwei Du; Ping Huang; Bruce T Liang; Michael A Frohman
Journal:  Mol Biol Cell       Date:  2004-01-12       Impact factor: 4.138

8.  An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.

Authors:  Juha R Savinainen; Susanna M Saario; Riku Niemi; Tomi Järvinen; Jarmo T Laitinen
Journal:  Br J Pharmacol       Date:  2003-11-17       Impact factor: 8.739

9.  Effects of ADP-ribosylation of GTP-binding protein by pertussis toxin on immunoglobulin E-dependent and -independent histamine release from mast cells and basophils.

Authors:  H Saito; F Okajima; T F Molski; R I Sha'afi; M Ui; T Ishizaka
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

10.  The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.

Authors:  M J Millan; A Gobert; F Lejeune; A Dekeyne; A Newman-Tancredi; V Pasteau; J-M Rivet; D Cussac
Journal:  J Pharmacol Exp Ther       Date:  2003-05-15       Impact factor: 4.030

View more
  18 in total

1.  Non-FcεR bearing mast cells secrete sufficient interleukin-4 to control Francisella tularensis replication within macrophages.

Authors:  Prea Thathiah; Shilpa Sanapala; Annette R Rodriguez; Jieh-Juen Yu; Ashlesh K Murthy; M Neal Guentzel; Thomas G Forsthuber; James P Chambers; Bernard P Arulanandam
Journal:  Cytokine       Date:  2011-05-12       Impact factor: 3.861

2.  Anatomical location of LPA1 activation and LPA phospholipid precursors in rodent and human brain.

Authors:  Estibaliz González de San Román; Iván Manuel; María Teresa Giralt; Jerold Chun; Guillermo Estivill-Torrús; Fernando Rodríguez de Fonseca; Luis Javier Santín; Isidro Ferrer; Rafael Rodríguez-Puertas
Journal:  J Neurochem       Date:  2015-04-27       Impact factor: 5.372

3.  Mast cell degranulation mediates compound 48/80-induced hyperalgesia in mice.

Authors:  Devavani Chatterjea; Abigail Wetzel; Madison Mack; Camilla Engblom; Juliann Allen; Carolina Mora-Solano; Luisa Paredes; Evelyn Balsells; Tijana Martinov
Journal:  Biochem Biophys Res Commun       Date:  2012-07-22       Impact factor: 3.575

4.  Tachykinin-1 receptor antagonism suppresses substance-P- and compound 48/80-induced mast cell activation from rat mast cells expressing functional mas-related GPCR B3.

Authors:  Muhammad N A Sahid; Shuang Liu; Masaki Mogi; Kazutaka Maeyama
Journal:  Inflamm Res       Date:  2020-01-28       Impact factor: 4.575

5.  Inhibitory effects of curcumin on passive cutaneous anaphylactoid response and compound 48/80-induced mast cell activation.

Authors:  Yun-Ho Choi; Guang-Hai Yan; Ok Hee Chai; Chang Ho Song
Journal:  Anat Cell Biol       Date:  2010-03-31

6.  Mast cell degranulation activates a pain pathway underlying migraine headache.

Authors:  Dan Levy; Rami Burstein; Vanessa Kainz; Moshe Jakubowski; Andrew M Strassman
Journal:  Pain       Date:  2007-04-24       Impact factor: 6.961

7.  Phospholipase D signaling in serotonin-induced mitogenesis of pulmonary artery smooth muscle cells.

Authors:  Y Liu; B L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-07-11       Impact factor: 5.464

Review 8.  ATX-LPA receptor axis in inflammation and cancer.

Authors:  Shuying Liu; Mandi Murph; Nattapon Panupinthu; Gordon B Mills
Journal:  Cell Cycle       Date:  2009-11-27       Impact factor: 4.534

9.  Codeine induces human mast cell chemokine and cytokine production: involvement of G-protein activation.

Authors:  C H Sheen; R P Schleimer; M Kulka
Journal:  Allergy       Date:  2007-05       Impact factor: 13.146

10.  Autocrine hemokinin-1 functions as an endogenous adjuvant for IgE-mediated mast cell inflammatory responses.

Authors:  Tina L Sumpter; Chin H Ho; Anna R Pleet; Olga A Tkacheva; William J Shufesky; Darling M Rojas-Canales; Adrian E Morelli; Adriana T Larregina
Journal:  J Allergy Clin Immunol       Date:  2014-09-04       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.